The Ruhr University Bochum team’s May 2026 JHEP Reports paper marks the first demonstration that CRISPR-Cas13d can selectively degrade hepatitis E virus (HEV) RNA, reducing infectious particle production in human cell lines while preserving viability. Unlike the DNA-cleaving Cas9 systems that dominate headlines, Cas13d acts directly on viral transcripts, offering a precision strike suited to RNA viruses like HEV. The study is strictly observational and in-vitro: no animal models or human subjects were used, sample sizes were limited to standard laboratory replicates, and no industry conflicts are declared. Three to four crRNAs targeting conserved ORF1 regions achieved broad coverage across known HEV genotypes, a bioinformatics insight that could blunt mutational escape. Yet the original MedicalXpress coverage omits the larger pattern—prior Cas13 antiviral work against influenza and SARS-CoV-2 (e.g., Blanchard et al., Nature Biotechnology 2021; Abbott et al., Cell 2020) already proved RNA knockdown feasible but repeatedly stumbled at systemic delivery and off-target transcript effects. HEV’s fecal-oral transmission and chronic risk in immunocompromised patients make liver-targeted delivery even more critical; lipid nanoparticles or AAV vectors successful in recent mRNA therapeutics remain untested here. The paper correctly flags these translational hurdles, but understates that existing ribavirin regimens, though imperfect, already achieve viral clearance in many transplant recipients, raising the bar for any new modality. If Cas13d can be packaged for hepatocyte delivery without triggering innate immune sensing, it may complement rather than replace current options; otherwise it risks joining the long list of elegant but clinically distant gene-editing antivirals.